S3 Table. Baseline patients' characteristics according to the second-line chemotherapy

	Fluoropyrimidine-oxaliplatin doublets (n=78)	Fluoropyrimidine monotherapy (n=37)	p-value
Sex			0.51
Male	44 (56.4)	24 (64.9)	
Female	34 (43.6)	13 (35.1)	
Age, median (range, yr)	61.0 (35-79)	60.0 (44-73)	0.44
ECOG performance status			0.34
0	32 (41.0)	11 (29.7)	
1-2	46 (59.0)	26 (70.3)	
CA19-9			< 0.01
Normal	8 (10.3)	9 (24.3)	
Elevated	35 (44.9)	27 (73.0)	
Not evaluated	35 (44.9)	1 (2.7)	
Albumin, median (IQR, g/dL)	3.5 (3.0-3.7)	3.5 (3.1-3.9)	0.23
NLR, median (IQR)	2.2 (1.6-3.1)	2.1 (1.3-3.6)	0.53
PLR, median (IQR)	155.2 (104.7-224.9)	151.1 (112.1-203.5)	0.72
No. of metastatic sites			0.07
0-1	35 (44.9)	24 (64.9)	
≥ 2	43 (55.1)	13 (35.1)	
Site(s) of metastases			
Liver	50 (64.1)	19 (51.4)	0.27
Lung	19 (24.4)	10 (27.0)	0.94
Bone	2 (2.6)	5 (13.5)	0.06
Peritoneum	33 (42.3)	11 (29.7)	0.28
Lymph node	29 (37.2)	11 (29.7)	0.57
1L-TTP, median (95% CI, mo)	5.75 (4.83-6.68)	7.33 (6.08-8.59)	0.08

Values are presented as number (%) unless otherwise indicated. ECOG, Eastern Cooperative Oncology Group; CA19-9, carbohydrate antigen 19-9; IQR, interquartile range; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; 1L, first line; TTP, time to progression; CI, confidence interval.